An observational study in CAH - 21-Hydroxylase Deficiency, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 7 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Adrenal Hyperplasia, Congenital with a site in France — 6 open to participants now, 8 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · France.
Among the 21 studies in Adrenal Hyperplasia, Congenital with a site in France, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2026, is one of 10 observational ones, and was the 17th registered.
102 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 29 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →6 of the 21 studies in Adrenal Hyperplasia, Congenital with a site in France are open now. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–65 · Women only
Crinetics Pharmaceuticals Inc. · Sites in France, United States, Argentina and 10 more countries
Ages 1–17
Crinetics Pharmaceuticals Inc. · Sites in France, United States, Argentina and 12 more countries
Ages 18–74
H. Lundbeck A/S · Sites in France, United States, Denmark and 6 more countries
Ages 18–70
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7
First in 2008; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 61 across 44 observational studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 76 across the 11 interventional studies, 94 across the 10 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 6 studies filed under Adrenal Hyperplasia, Congenital — fewer than ten, so there is no comparison to draw.
4 of the studies in Adrenal Hyperplasia, Congenital with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144163Phase 3Crinetics Pharmaceuticals Inc.A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | 2027-05 |
| NCT07781267University Hospital, LillePediatric Congenital Adrenal Hyperplasia Management: Regret and Long-term Outcomes | 2027-03-08 |
| NCT06900153Assistance Publique - Hôpitaux de ParisParenting and CAH - 21-hydroxylase Deficiency | 2027-03-13 |
| NCT07718230Assistance Publique - Hôpitaux de ParisEvaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Adrenal Hyperplasia, Congenital with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Congenital adrenal hyperplasia (CAH) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis enzymes. 21-hydroxylase deficiency (21OHD), related to mutations of the CYP21A2 gene, is involved in 90 to 95% of CAH cases. Depending on the severity of the mutations of this gene, there are severe forms known as "classic" (FC), with neonatal onset, and moderate forms known as "non-classic" (FNC), with onset later in childhood or after puberty. The classic form includes the salt-wasting form and the pure virilizing form, depending on the degree of aldosterone deficiency. The sexuality and fertility of women with classic 21OHD deficiency are impaired by several factors such as disruption of the gonadotropic axis due to overproduction of androgens and progesterone by the adrenal glands, and mechanical and psychological factors related to genital surgery. The fertility of these women improves over time, largely due to earlier treatment of CAH, improved therapeutic compliance and surgical advances in genital reconstruction leading to an increase in the percentage of patients who are sexually active. However, there is little data available, and even less on the course of pregnancy, its complications and its outcomes.
Women with HCS due to 21-hydroxylase deficiency, confirmed genetically, and monitored in one of the participating Endocrinology departments affiliated with the CRMR of the FIRENDO network
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
the investigator calls the patient and asks her questions about her parental project and her pregnancies
to describe how pregnancies are achieved: spontaneous or induced, if induced by which ART technique.
Information on how the pregnancy was achieved will be collected from the medical file and will be supplemented on the day of inclusion by a telephone questionnaire to the patient, if the data in the file do not provide answers to the study's questions.
Time frame: Day 1
Describe the existence of a parental project among the women in the cohort
The description of the parental project will be based on the patients' declaration of the presence or absence of a desire to have children, and if not, what the reasons were
Time frame: Day 1
Describe obstetric complications
The description of obstetrical complications (GEU, miscarriages, in utero fetal death, IUGR, gestational diabetes, hypertension, pre-eclampsia, HELLP syndrome, cholestasis gravidarum, term of delivery, spontaneous or induced labor, birth weight, breastfeeding if desired) will be based on data from pregnancy and childbirth follow-up reports.
Time frame: Day 1
Describe the hormonal substitution adjustments.
The description of hormone replacement adjustments will be based on the prescription of Hydrocortisone and Fludrocortisone.
Time frame: Day 1
Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adrenal Hyperplasia, Congenital →
Assistance Publique - Hôpitaux de Paris →